Related Experiment Video

Updated: May 12, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Retreatment with talquetamab and pomalidomide in triple-class-BCMA-GPRC5D refractory myeloma

Kian J Rahbari1, Gliceida M Galarza Fortuna2, Bhagirathbhai Dholaria1,3

  • 1Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

British Journal of Haematology
|May 10, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
BCMAGPRC5DT‐cell redirecting therapyimmunotherapymultiple myelomamulti‐class refractory multiple myelomapomalidomidetalquetamabtriple‐class refractory multiple myeloma

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...